FDA approves cenobamate (XCopri) tablets for adults with partial-onset seizures -

FDA approves cenobamate (XCopri) tablets for adults with partial-onset seizures
Information type: Media and commentaries
Source: US Food and Drug Administration
Specialities: Neurological disorders
Summary
Approval was based on two placebo-controlled RCTS (n=655) which showed doses of 100, 200, and 400 milligrams mg daily of XCopri reduced percent of seizures per 28 days more effectively compared to placebo group.
UKMi comment

Cenobamate is sodium channel blocker, with a binding site different from that of classical sodium channel blocking drugs. It enhances GABAergic transmission by increasing presynaptic GABA release. In the EU, cenobamate is currently under investigation in phase 3 clinical trials for adjunctive partial focal epilepsy therapy.
Related links: